Study guide

Screening pathways and primary CVD prevention

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Screening pathways and primary CVD prevention

Key Takeaways Explain This Topic AI

A negative screening test does not dismiss concerning symptoms.

Routine cervical screening uses HPV testing at five-year intervals for eligible people.

A screening programme needs access to confirmatory diagnosis and treatment, not detection alone.

Last updated: October 2026

1. National Bowel Cancer Screening Program (NBCSP)

NBCSP entry: People aged 45–49 request their first kit; people aged 50–74 are routinely mailed biennial kits. A completed program round supports future two-year invitations. Assess symptoms diagnostically rather than relying on screening.

Modality : Immunochemical Faecal Occult Blood Test ( iFOBT ). The iFOBT detects the globin portion of human hemoglobin. Because globin is rapidly degraded by upper gastrointestinal enzymes, the test is highly specific for lower gastrointestinal bleeding . Unlike older guaiac-based tests, iFOBT requires no dietary restrictions (such as avoiding red meat or vitamin C).

Management of a Positive iFOBT :

Golden Rule : Never repeat the iFOBT to confirm a positive result.

Positive iFOBT: Refer promptly for appropriate colonoscopy. Do not repeat iFOBT to “clear” a positive result; there is no universal national mandatory 30-day colonoscopy deadline.

Approximately 1 in 30 people with a positive iFOBT will be diagnosed with colorectal cancer, and 1 in 2 will have an advanced adenoma or polyp.

Symptomatic Patients : The NBCSP is strictly for asymptomatic population screening. Patients presenting with rectal bleeding, unexplained persistent altered bowel habit, iron-deficiency anaemia, or palpable abdominal masses must be investigated with direct colonoscopy, never sent an iFOBT.

2. BreastScreen Australia

Target Cohort : Asymptomatic women aged 50 to 74 years receive biennial invitation letters. Women aged 40 to 49 years and women aged ≥ 75 years \ge 75\text{ years} ≥ 75 years are also eligible for free screening upon request, but do not receive automated invitations.

Modality : Bilateral two-view screening mammography (craniocaudal and mediolateral oblique views), independently read by two screening radiologists. If findings disagree, an independent third radiologist reviews the images.

Asymptomatic vs Symptomatic Presentation :

BreastScreen is exclusively designed for asymptomatic women.

Any woman presenting with a focal breast lump, localized persistent breast pain, nipple inversion, blood-stained nipple discharge, or skin changes (peau d'orange) must be investigated using the Triple Test in diagnostic clinical practice:

Clinical breast examination.

Diagnostic breast imaging (mammography ± \pm ± ultrasound).

Pathological assessment (core biopsy or fine-needle aspiration cytology).

3. National Cervical Screening Program (NCSP)

Eligibility & Interval : Women and people with a cervix aged 25 to 74 years , screened every 5 years .

Modality : Primary nucleic acid testing for oncogenic Human Papillomavirus (HPV) genotypes. This replaced 2-yearly Papanicolaou (Pap) smear cytology, providing superior sensitivity for high-grade cervical dysplasia.

Universal Self-Collection Option : All eligible screening participants have the choice to collect their own sample using a simple vaginal swab, or to have a clinician perform a speculum examination and cervical sample collection. High-level evidence confirms that self-collected vaginal swabs have equivalent sensitivity to clinician-collected cervical samples for detecting high-risk HPV.

NCSP Management Algorithm :

HPV Not Detected : Patient is reassured and returns to routine 5-yearly recall.

HPV Detected (Types 16 and/or 18) : Highest oncogenic risk (types 16 and 18 cause > 70 % > 70\% > 70% of cervical cancers). Requires direct referral for colposcopy , regardless of liquid-based cytology findings.

HPV Detected (Non-16/18 High-Risk Types) : Reflex liquid-based cytology (LBC) is performed on the specimen:

If cytology is negative (normal) or low-grade (pLSIL): Repeat HPV test in 12 months .

If cytology is high-grade (HSIL, ASC-H) or glandular abnormality: Immediate referral for colposcopy .

Absolute Cardiovascular Disease Risk Assessment: The 2023 Australian Guideline

The 2023 Australian Guideline for assessing and managing cardiovascular disease risk replaced the older 2012 Framingham-based risk charts with the PREDICT-based Australian CVD Risk Calculator .

Eligibility for Risk Assessment

Asymptomatic adults aged 45 to 79 years without known atherosclerotic cardiovascular disease.

Aboriginal and Torres Strait Islander adults aged 30 to 79 years .

Adults with diabetes aged 35 to 79 years .

Risk Factors Integrated into the PREDICT Equation

Age, sex, smoking status, systolic blood pressure, use of blood pressure-lowering medication, total cholesterol, HDL-cholesterol, diabetes status, HbA1c, eGFR, urine albumin-to-creatinine ratio (ACR), and socioeconomic disadvantage index (SEIFA).

Clinically Determined High Risk (No Calculation Required)

Patients with any of the following clinical conditions are automatically classified as high risk ( ≥ 10 % \ge 10\% ≥ 10% 5-year risk) and must not be run through the calculator:

Moderate to severe chronic kidney disease (eGFR < 45 mL/min/1.73m 2 < 45\text{ mL/min/1.73m}^2 < 45 mL/min/1.73m 2 or persistent urine ACR > 25 mg/mmol > 25\text{ mg/mmol} > 25 mg/mmol in men, > 35 mg/mmol > 35\text{ mg/mmol} > 35 mg/mmol in women).

Current automatic high-risk conditions: Confirmed familial hypercholesterolaemia and moderate-to-severe CKD establish high risk without calculation. Old automatic categories based on diabetes after 60, severe BP or a lipid cut-off must not be carried into the 2023 calculator pathway.

  • 5-Year CVD Risk Stratification & Management
  • Therapeutic Targets in High-Risk Patients

Treatment goals: Individualise BP and lipid targets using the relevant disease guidance, tolerability and patient priorities. Primary-prevention risk categories alone do not impose the same LDL target as established ASCVD. Offer indicated blood-pressure and lipid-lowering treatment with lifestyle support and monitor effectiveness/adverse effects.

National Lung Cancer Screening Program

The program began in July 2025. Eligible asymptomatic people are aged 50–70, have at least 30 pack-years of smoking and currently smoke or quit within the past ten years. Screening uses low-dose CT, generally every two years, with nodule follow-up governed by the program pathway. Symptoms such as haemoptysis or unexplained weight loss need diagnostic assessment rather than a screening appointment. Discuss radiation, incidental findings and follow-up, and offer smoking-cessation support without stigma. Eligibility and the cessation interval must be assessed accurately; one pack per day for 30 years is 30 pack-years, as is two packs for 15 years.

Self-collected HPV results

A self-collected vaginal swab tests HPV but does not supply cervical cells for reflex liquid-based cytology. Non-16/18 HPV detected on a self-collected sample generally requires a clinician-collected cervical specimen for LBC. HPV16/18 leads to colposcopy regardless, with further sampling arranged through that pathway. Screening is for asymptomatic people; persistent bleeding or a visible cervical lesion requires the symptom/diagnostic pathway.

Primary references (checked 7 October 2026): Current Immunisation Handbook ; 2026 adult pneumococcal update ; National lung screening .